티르제파티드

티르제파티드 C화학적 특성, 용도, 생산

개요

Tirzepatide (LY3298176) was developed as a dual agonist to both GLP-1 and gastric inhibitory polypeptide (GIP) receptors (Frias et al., 2018). Similar to GLP-1, GIP is an incretin hormone that functions to induce insulin secretion.

용도

Tirzepatide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes.  Controlling high blood sugar helps prevent kidney damage, blindness,  nerve problems, loss of limbs, and sexual function problems.

상품명

brand name: Mounjaro

Mechanism of action

It works to stimulate first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner.  Tirzepatide was also shown to delay gastric emptying, lower fasting and  postprandial glucose concentration, decrease food intake, 4 and reduce body weight in patients with type 2 diabetes.

부작용

The overall safety and tolerability profile of tirzepatide was similar to other incretin-based therapies that have been approved for the treatment of obesity. This said, reported side effects were considerable, especially as dosage levels increased. The most common adverse events were nausea (~30%), diarrhea (~20%), constipation (~15%) and vomiting (~10%).
If tirzepatide gets approved as a both a blood glucose control and anti-obesity agent, it could become a blockbuster drug. However, this isn’t a sure thing. It will have to overcome pricing and reimbursement obstacles, which have plagued similar treatments.

Clinical claims and research

Tirzepatide (Eli Lilly), a novel, once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) receptor and GLP-1 RA combination drug, has been developed to treat patients with T2DM. The manufacturer (Eli Lilly) announced the submission of a biologics license application with priority review to the FDA for T2DM on October 27, 2021, with a decision expected in mid-2022.

Research

Tirzepatide is in phase 3 clinical development at Eli Lilly and Company for blood glucose management in adults with type 2 diabetes, chronic weight management, and obesity-related heart failure with preserved ejection fraction. In addition, Tirzepatide is being studied as a potential treatment for non-alcoholic steatohepatitis (NASH). The molecule comprises a 39 amino acid peptide backbone and a side chain at residue 20. Of the 39 amino acids, 37 are naturally occurring (or coded), while two are noncoded aminoisobutyric acid residues at positions 2 and 13[1].

티르제파티드 준비 용품 및 원자재

원자재

준비 용품

티르제파티드 공급 업체

공급자	전화	이메일	국가	제품 수	이점
Shanghai Longyu Biotechnology Co., Ltd.	+8619521488211	info@longyupharma.com	China	2556	58
Hubei Yuanao Technology CO Ltd	+86-15377628618 +86-15377628618	info@yuanaotech.com	China	6	58
Huaian Banting Trading Co., Ltd.	+86-15833978697	sales1@bantingpeptide.com	China	85	58
BOC Sciences	+1-631-485-4226	inquiry@bocsci.com	United States	19552	58
Zibo Hangyu Biotechnology Development Co., Ltd	+86-0533-2185556 +8615965530500	nickzhang@hangyubiotech.com	China	10987	58
Shaanxi Xianhe Biotech Co., Ltd	+8617709210191	Jerry@xhobio.com	China	885	58
Rixing Chemical CO.,LTD.	+86-852-57055271 +8613237129059	sales@rixingbiz.com	China	209	58
Zhangzhou Sinobioway Peptide Co.,Ltd.	15659861111	SINOPEPT@GMAIL.COM	China	44	58
Wuhan Haorong Biotechnology Co.,ltd	+86-18565342920; +8618565342920	sales@chembj.net	China	299	58
Shenzhen Aoxi Technology Co., Ltd.	+852-46424790 +852-46424790	frank88rawpowder@outlook.com	China	152	58

티르제파티드 관련 검색: